maxarray™ prostate cancer & bph tissue microarray slides Search Results


frozen prostate tumors  (Eppley Laboratory Inc)
90
Eppley Laboratory Inc frozen prostate tumors
Frozen Prostate Tumors, supplied by Eppley Laboratory Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/frozen prostate tumors/product/Eppley Laboratory Inc
Average 90 stars, based on 1 article reviews
frozen prostate tumors - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
prostate tumor tissue microarrays  (Biomax Inc)
86
Biomax Inc prostate tumor tissue microarrays
Prostate Tumor Tissue Microarrays, supplied by Biomax Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/prostate tumor tissue microarrays/product/Biomax Inc
Average 86 stars, based on 1 article reviews
prostate tumor tissue microarrays - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier
vevo 2200 photoacoustic scanner  (FUJIFILM)
90
FUJIFILM vevo 2200 photoacoustic scanner
Vevo 2200 Photoacoustic Scanner, supplied by FUJIFILM, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/vevo 2200 photoacoustic scanner/product/FUJIFILM
Average 90 stars, based on 1 article reviews
vevo 2200 photoacoustic scanner - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
prostate tumors  (Johns Hopkins HealthCare)
90
Johns Hopkins HealthCare prostate tumors
Prostate Tumors, supplied by Johns Hopkins HealthCare, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/prostate tumors/product/Johns Hopkins HealthCare
Average 90 stars, based on 1 article reviews
prostate tumors - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
cancer pathwayfinder  (SuperArray Bioscience Corporation)
90
SuperArray Bioscience Corporation cancer pathwayfinder
In vivo therapeutic and chemopreventive effects of ASC-J9 in genetically engineered mouse PCa models. A: Early treatment with ASC-J9 suppressed tumor initiation/progression in the <t>TRAMP</t> mouse model. The chemopreventive effects of ASC-J9 were demonstrated by early i.p. injection at 8 weeks old with continued treatment until 23 to 24 weeks old. The prostates (prostate tumors or precancerous lesions) were harvested and photographed (left panel), and the prostate mass weights were calculated (right panel). N = 6 mice per group. B: ASC-J9 treatment suppressed the growth of TRAMP tumor chunks <t>s.c.</t> <t>implanted</t> into SCID mice. After 4 weeks of vehicle or ASC-J9 injection, the s.c. tumors were harvested and photographed (top panel), and the tumor weights were calculated (bottom panel). N = 6 for each group. C: TRAMP prostate tumor growth was inhibited by ASC-J9 after subrenal capsule implantation in SCID mice. After 4 weeks of vehicle or ASC-J9 injection, tumors were harvested and photographed (left panel), and the tumor weights were determined (right panel). N = 3 for each group. D: ASC-J9 displayed chemopreventive effects in the Pten+/− mouse model. ASC-J9 was administrated to 6-month-old Pten+/− mice, and the dorsolateral prostates were harvested 2 months after injection. Histologic examination of 8-month-old Pten+/+ DMSO, Pten+/− DMSO, and Pten+/− ASC-J9–treated prostates were subjected to H&E staining (left panel). The arrows point to the high-grade PIN lesions. Quantitation of high-grade PIN lesions is provided in the right panel. N = 5 to 6 mice per group. Error bars = mean ± SEM. Scale bars: 200 μm (original magnification, ×100) and 50μm (original magnifcation, ×400).
Cancer Pathwayfinder, supplied by SuperArray Bioscience Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cancer pathwayfinder/product/SuperArray Bioscience Corporation
Average 90 stars, based on 1 article reviews
cancer pathwayfinder - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
commercial prostate tumor tissue microarrays  (SuperBioChips)
90
SuperBioChips commercial prostate tumor tissue microarrays
In vivo therapeutic and chemopreventive effects of ASC-J9 in genetically engineered mouse PCa models. A: Early treatment with ASC-J9 suppressed tumor initiation/progression in the <t>TRAMP</t> mouse model. The chemopreventive effects of ASC-J9 were demonstrated by early i.p. injection at 8 weeks old with continued treatment until 23 to 24 weeks old. The prostates (prostate tumors or precancerous lesions) were harvested and photographed (left panel), and the prostate mass weights were calculated (right panel). N = 6 mice per group. B: ASC-J9 treatment suppressed the growth of TRAMP tumor chunks <t>s.c.</t> <t>implanted</t> into SCID mice. After 4 weeks of vehicle or ASC-J9 injection, the s.c. tumors were harvested and photographed (top panel), and the tumor weights were calculated (bottom panel). N = 6 for each group. C: TRAMP prostate tumor growth was inhibited by ASC-J9 after subrenal capsule implantation in SCID mice. After 4 weeks of vehicle or ASC-J9 injection, tumors were harvested and photographed (left panel), and the tumor weights were determined (right panel). N = 3 for each group. D: ASC-J9 displayed chemopreventive effects in the Pten+/− mouse model. ASC-J9 was administrated to 6-month-old Pten+/− mice, and the dorsolateral prostates were harvested 2 months after injection. Histologic examination of 8-month-old Pten+/+ DMSO, Pten+/− DMSO, and Pten+/− ASC-J9–treated prostates were subjected to H&E staining (left panel). The arrows point to the high-grade PIN lesions. Quantitation of high-grade PIN lesions is provided in the right panel. N = 5 to 6 mice per group. Error bars = mean ± SEM. Scale bars: 200 μm (original magnification, ×100) and 50μm (original magnifcation, ×400).
Commercial Prostate Tumor Tissue Microarrays, supplied by SuperBioChips, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/commercial prostate tumor tissue microarrays/product/SuperBioChips
Average 90 stars, based on 1 article reviews
commercial prostate tumor tissue microarrays - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
prostate tumor  (Neoplas GmbH)
90
Neoplas GmbH prostate tumor
In vivo therapeutic and chemopreventive effects of ASC-J9 in genetically engineered mouse PCa models. A: Early treatment with ASC-J9 suppressed tumor initiation/progression in the <t>TRAMP</t> mouse model. The chemopreventive effects of ASC-J9 were demonstrated by early i.p. injection at 8 weeks old with continued treatment until 23 to 24 weeks old. The prostates (prostate tumors or precancerous lesions) were harvested and photographed (left panel), and the prostate mass weights were calculated (right panel). N = 6 mice per group. B: ASC-J9 treatment suppressed the growth of TRAMP tumor chunks <t>s.c.</t> <t>implanted</t> into SCID mice. After 4 weeks of vehicle or ASC-J9 injection, the s.c. tumors were harvested and photographed (top panel), and the tumor weights were calculated (bottom panel). N = 6 for each group. C: TRAMP prostate tumor growth was inhibited by ASC-J9 after subrenal capsule implantation in SCID mice. After 4 weeks of vehicle or ASC-J9 injection, tumors were harvested and photographed (left panel), and the tumor weights were determined (right panel). N = 3 for each group. D: ASC-J9 displayed chemopreventive effects in the Pten+/− mouse model. ASC-J9 was administrated to 6-month-old Pten+/− mice, and the dorsolateral prostates were harvested 2 months after injection. Histologic examination of 8-month-old Pten+/+ DMSO, Pten+/− DMSO, and Pten+/− ASC-J9–treated prostates were subjected to H&E staining (left panel). The arrows point to the high-grade PIN lesions. Quantitation of high-grade PIN lesions is provided in the right panel. N = 5 to 6 mice per group. Error bars = mean ± SEM. Scale bars: 200 μm (original magnification, ×100) and 50μm (original magnifcation, ×400).
Prostate Tumor, supplied by Neoplas GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/prostate tumor/product/Neoplas GmbH
Average 90 stars, based on 1 article reviews
prostate tumor - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
prostate tumor  (PharmaMar USA)
90
PharmaMar USA prostate tumor
In vivo therapeutic and chemopreventive effects of ASC-J9 in genetically engineered mouse PCa models. A: Early treatment with ASC-J9 suppressed tumor initiation/progression in the <t>TRAMP</t> mouse model. The chemopreventive effects of ASC-J9 were demonstrated by early i.p. injection at 8 weeks old with continued treatment until 23 to 24 weeks old. The prostates (prostate tumors or precancerous lesions) were harvested and photographed (left panel), and the prostate mass weights were calculated (right panel). N = 6 mice per group. B: ASC-J9 treatment suppressed the growth of TRAMP tumor chunks <t>s.c.</t> <t>implanted</t> into SCID mice. After 4 weeks of vehicle or ASC-J9 injection, the s.c. tumors were harvested and photographed (top panel), and the tumor weights were calculated (bottom panel). N = 6 for each group. C: TRAMP prostate tumor growth was inhibited by ASC-J9 after subrenal capsule implantation in SCID mice. After 4 weeks of vehicle or ASC-J9 injection, tumors were harvested and photographed (left panel), and the tumor weights were determined (right panel). N = 3 for each group. D: ASC-J9 displayed chemopreventive effects in the Pten+/− mouse model. ASC-J9 was administrated to 6-month-old Pten+/− mice, and the dorsolateral prostates were harvested 2 months after injection. Histologic examination of 8-month-old Pten+/+ DMSO, Pten+/− DMSO, and Pten+/− ASC-J9–treated prostates were subjected to H&E staining (left panel). The arrows point to the high-grade PIN lesions. Quantitation of high-grade PIN lesions is provided in the right panel. N = 5 to 6 mice per group. Error bars = mean ± SEM. Scale bars: 200 μm (original magnification, ×100) and 50μm (original magnifcation, ×400).
Prostate Tumor, supplied by PharmaMar USA, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/prostate tumor/product/PharmaMar USA
Average 90 stars, based on 1 article reviews
prostate tumor - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
prostate tumor samples  (Johns Hopkins HealthCare)
90
Johns Hopkins HealthCare prostate tumor samples
In vivo therapeutic and chemopreventive effects of ASC-J9 in genetically engineered mouse PCa models. A: Early treatment with ASC-J9 suppressed tumor initiation/progression in the <t>TRAMP</t> mouse model. The chemopreventive effects of ASC-J9 were demonstrated by early i.p. injection at 8 weeks old with continued treatment until 23 to 24 weeks old. The prostates (prostate tumors or precancerous lesions) were harvested and photographed (left panel), and the prostate mass weights were calculated (right panel). N = 6 mice per group. B: ASC-J9 treatment suppressed the growth of TRAMP tumor chunks <t>s.c.</t> <t>implanted</t> into SCID mice. After 4 weeks of vehicle or ASC-J9 injection, the s.c. tumors were harvested and photographed (top panel), and the tumor weights were calculated (bottom panel). N = 6 for each group. C: TRAMP prostate tumor growth was inhibited by ASC-J9 after subrenal capsule implantation in SCID mice. After 4 weeks of vehicle or ASC-J9 injection, tumors were harvested and photographed (left panel), and the tumor weights were determined (right panel). N = 3 for each group. D: ASC-J9 displayed chemopreventive effects in the Pten+/− mouse model. ASC-J9 was administrated to 6-month-old Pten+/− mice, and the dorsolateral prostates were harvested 2 months after injection. Histologic examination of 8-month-old Pten+/+ DMSO, Pten+/− DMSO, and Pten+/− ASC-J9–treated prostates were subjected to H&E staining (left panel). The arrows point to the high-grade PIN lesions. Quantitation of high-grade PIN lesions is provided in the right panel. N = 5 to 6 mice per group. Error bars = mean ± SEM. Scale bars: 200 μm (original magnification, ×100) and 50μm (original magnifcation, ×400).
Prostate Tumor Samples, supplied by Johns Hopkins HealthCare, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/prostate tumor samples/product/Johns Hopkins HealthCare
Average 90 stars, based on 1 article reviews
prostate tumor samples - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
tumors  (Novus Biologicals)
93
Novus Biologicals tumors
In vivo therapeutic and chemopreventive effects of ASC-J9 in genetically engineered mouse PCa models. A: Early treatment with ASC-J9 suppressed tumor initiation/progression in the <t>TRAMP</t> mouse model. The chemopreventive effects of ASC-J9 were demonstrated by early i.p. injection at 8 weeks old with continued treatment until 23 to 24 weeks old. The prostates (prostate tumors or precancerous lesions) were harvested and photographed (left panel), and the prostate mass weights were calculated (right panel). N = 6 mice per group. B: ASC-J9 treatment suppressed the growth of TRAMP tumor chunks <t>s.c.</t> <t>implanted</t> into SCID mice. After 4 weeks of vehicle or ASC-J9 injection, the s.c. tumors were harvested and photographed (top panel), and the tumor weights were calculated (bottom panel). N = 6 for each group. C: TRAMP prostate tumor growth was inhibited by ASC-J9 after subrenal capsule implantation in SCID mice. After 4 weeks of vehicle or ASC-J9 injection, tumors were harvested and photographed (left panel), and the tumor weights were determined (right panel). N = 3 for each group. D: ASC-J9 displayed chemopreventive effects in the Pten+/− mouse model. ASC-J9 was administrated to 6-month-old Pten+/− mice, and the dorsolateral prostates were harvested 2 months after injection. Histologic examination of 8-month-old Pten+/+ DMSO, Pten+/− DMSO, and Pten+/− ASC-J9–treated prostates were subjected to H&E staining (left panel). The arrows point to the high-grade PIN lesions. Quantitation of high-grade PIN lesions is provided in the right panel. N = 5 to 6 mice per group. Error bars = mean ± SEM. Scale bars: 200 μm (original magnification, ×100) and 50μm (original magnifcation, ×400).
Tumors, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/tumors/product/Novus Biologicals
Average 93 stars, based on 1 article reviews
tumors - by Bioz Stars, 2026-05
93/100 stars
  Buy from Supplier
pc 3 prostate tumor cells  (DSMZ)
95
DSMZ pc 3 prostate tumor cells
In vivo therapeutic and chemopreventive effects of ASC-J9 in genetically engineered mouse PCa models. A: Early treatment with ASC-J9 suppressed tumor initiation/progression in the <t>TRAMP</t> mouse model. The chemopreventive effects of ASC-J9 were demonstrated by early i.p. injection at 8 weeks old with continued treatment until 23 to 24 weeks old. The prostates (prostate tumors or precancerous lesions) were harvested and photographed (left panel), and the prostate mass weights were calculated (right panel). N = 6 mice per group. B: ASC-J9 treatment suppressed the growth of TRAMP tumor chunks <t>s.c.</t> <t>implanted</t> into SCID mice. After 4 weeks of vehicle or ASC-J9 injection, the s.c. tumors were harvested and photographed (top panel), and the tumor weights were calculated (bottom panel). N = 6 for each group. C: TRAMP prostate tumor growth was inhibited by ASC-J9 after subrenal capsule implantation in SCID mice. After 4 weeks of vehicle or ASC-J9 injection, tumors were harvested and photographed (left panel), and the tumor weights were determined (right panel). N = 3 for each group. D: ASC-J9 displayed chemopreventive effects in the Pten+/− mouse model. ASC-J9 was administrated to 6-month-old Pten+/− mice, and the dorsolateral prostates were harvested 2 months after injection. Histologic examination of 8-month-old Pten+/+ DMSO, Pten+/− DMSO, and Pten+/− ASC-J9–treated prostates were subjected to H&E staining (left panel). The arrows point to the high-grade PIN lesions. Quantitation of high-grade PIN lesions is provided in the right panel. N = 5 to 6 mice per group. Error bars = mean ± SEM. Scale bars: 200 μm (original magnification, ×100) and 50μm (original magnifcation, ×400).
Pc 3 Prostate Tumor Cells, supplied by DSMZ, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pc 3 prostate tumor cells/product/DSMZ
Average 95 stars, based on 1 article reviews
pc 3 prostate tumor cells - by Bioz Stars, 2026-05
95/100 stars
  Buy from Supplier
pearson chi-square  (CH Instruments)
90
CH Instruments pearson chi-square
In vivo therapeutic and chemopreventive effects of ASC-J9 in genetically engineered mouse PCa models. A: Early treatment with ASC-J9 suppressed tumor initiation/progression in the <t>TRAMP</t> mouse model. The chemopreventive effects of ASC-J9 were demonstrated by early i.p. injection at 8 weeks old with continued treatment until 23 to 24 weeks old. The prostates (prostate tumors or precancerous lesions) were harvested and photographed (left panel), and the prostate mass weights were calculated (right panel). N = 6 mice per group. B: ASC-J9 treatment suppressed the growth of TRAMP tumor chunks <t>s.c.</t> <t>implanted</t> into SCID mice. After 4 weeks of vehicle or ASC-J9 injection, the s.c. tumors were harvested and photographed (top panel), and the tumor weights were calculated (bottom panel). N = 6 for each group. C: TRAMP prostate tumor growth was inhibited by ASC-J9 after subrenal capsule implantation in SCID mice. After 4 weeks of vehicle or ASC-J9 injection, tumors were harvested and photographed (left panel), and the tumor weights were determined (right panel). N = 3 for each group. D: ASC-J9 displayed chemopreventive effects in the Pten+/− mouse model. ASC-J9 was administrated to 6-month-old Pten+/− mice, and the dorsolateral prostates were harvested 2 months after injection. Histologic examination of 8-month-old Pten+/+ DMSO, Pten+/− DMSO, and Pten+/− ASC-J9–treated prostates were subjected to H&E staining (left panel). The arrows point to the high-grade PIN lesions. Quantitation of high-grade PIN lesions is provided in the right panel. N = 5 to 6 mice per group. Error bars = mean ± SEM. Scale bars: 200 μm (original magnification, ×100) and 50μm (original magnifcation, ×400).
Pearson Chi Square, supplied by CH Instruments, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pearson chi-square/product/CH Instruments
Average 90 stars, based on 1 article reviews
pearson chi-square - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

Image Search Results


In vivo therapeutic and chemopreventive effects of ASC-J9 in genetically engineered mouse PCa models. A: Early treatment with ASC-J9 suppressed tumor initiation/progression in the TRAMP mouse model. The chemopreventive effects of ASC-J9 were demonstrated by early i.p. injection at 8 weeks old with continued treatment until 23 to 24 weeks old. The prostates (prostate tumors or precancerous lesions) were harvested and photographed (left panel), and the prostate mass weights were calculated (right panel). N = 6 mice per group. B: ASC-J9 treatment suppressed the growth of TRAMP tumor chunks s.c. implanted into SCID mice. After 4 weeks of vehicle or ASC-J9 injection, the s.c. tumors were harvested and photographed (top panel), and the tumor weights were calculated (bottom panel). N = 6 for each group. C: TRAMP prostate tumor growth was inhibited by ASC-J9 after subrenal capsule implantation in SCID mice. After 4 weeks of vehicle or ASC-J9 injection, tumors were harvested and photographed (left panel), and the tumor weights were determined (right panel). N = 3 for each group. D: ASC-J9 displayed chemopreventive effects in the Pten+/− mouse model. ASC-J9 was administrated to 6-month-old Pten+/− mice, and the dorsolateral prostates were harvested 2 months after injection. Histologic examination of 8-month-old Pten+/+ DMSO, Pten+/− DMSO, and Pten+/− ASC-J9–treated prostates were subjected to H&E staining (left panel). The arrows point to the high-grade PIN lesions. Quantitation of high-grade PIN lesions is provided in the right panel. N = 5 to 6 mice per group. Error bars = mean ± SEM. Scale bars: 200 μm (original magnification, ×100) and 50μm (original magnifcation, ×400).

Journal: The American Journal of Pathology

Article Title: New Therapeutic Approach to Suppress Castration-Resistant Prostate Cancer Using ASC-J9 via Targeting Androgen Receptor in Selective Prostate Cells

doi: 10.1016/j.ajpath.2012.10.029

Figure Lengend Snippet: In vivo therapeutic and chemopreventive effects of ASC-J9 in genetically engineered mouse PCa models. A: Early treatment with ASC-J9 suppressed tumor initiation/progression in the TRAMP mouse model. The chemopreventive effects of ASC-J9 were demonstrated by early i.p. injection at 8 weeks old with continued treatment until 23 to 24 weeks old. The prostates (prostate tumors or precancerous lesions) were harvested and photographed (left panel), and the prostate mass weights were calculated (right panel). N = 6 mice per group. B: ASC-J9 treatment suppressed the growth of TRAMP tumor chunks s.c. implanted into SCID mice. After 4 weeks of vehicle or ASC-J9 injection, the s.c. tumors were harvested and photographed (top panel), and the tumor weights were calculated (bottom panel). N = 6 for each group. C: TRAMP prostate tumor growth was inhibited by ASC-J9 after subrenal capsule implantation in SCID mice. After 4 weeks of vehicle or ASC-J9 injection, tumors were harvested and photographed (left panel), and the tumor weights were determined (right panel). N = 3 for each group. D: ASC-J9 displayed chemopreventive effects in the Pten+/− mouse model. ASC-J9 was administrated to 6-month-old Pten+/− mice, and the dorsolateral prostates were harvested 2 months after injection. Histologic examination of 8-month-old Pten+/+ DMSO, Pten+/− DMSO, and Pten+/− ASC-J9–treated prostates were subjected to H&E staining (left panel). The arrows point to the high-grade PIN lesions. Quantitation of high-grade PIN lesions is provided in the right panel. N = 5 to 6 mice per group. Error bars = mean ± SEM. Scale bars: 200 μm (original magnification, ×100) and 50μm (original magnifcation, ×400).

Article Snippet: C: The Superarray (Cancer PathwayFinder) was used to identify gene expression changes in s.c. implanted TRAMP prostate tumors treated with vehicle or ASC-J9.

Techniques: In Vivo, Injection, Staining, Quantitation Assay